https://www.selleckchem.com/ph....armacological_epigen
rapeutic schemes that interfere with the progression and metastasis of HER2+ BC. Epithelial growth factor receptor (EGFR), as a malignancy marker, is overly expressed in multiple solid tumors including colorectal neoplasms, one of the most prevalent malignancies worldwide. The main objective of this study is to enhance the efficacy of anti-tumor therapy targeting EGFR by constructing a novel EGFR-specific immunotoxin (C-CUS ) based on Cetuximab and recombinant Cucurmosin (CUS ). E. coli BL21 (DE3) PlysS (E. coli) was used to
Like
Comment
Share
